NEW YORK (GenomeWeb) – A subset of breast cancers contain mutational signatures consistent with DNA mismatch repair (MMR) deficiency, new research reveals, suggesting that some individuals with the disease may benefit from immune checkpoint blockade immunotherapies similar to those being used in other types of cancer with MMR deficits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.